Mallinckrodt PLC (NYSE:MNK) has been assigned a consensus recommendation of “Hold” from the twenty-three research firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $41.96.

MNK has been the subject of several research analyst reports. Goldman Sachs Group initiated coverage on shares of Mallinckrodt in a report on Thursday, September 28th. They set a “buy” rating and a $55.00 price target for the company. Cantor Fitzgerald set a $52.00 price target on shares of Mallinckrodt and gave the stock a “buy” rating in a report on Monday, October 2nd. ValuEngine upgraded shares of Mallinckrodt from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Canaccord Genuity downgraded shares of Mallinckrodt from a “buy” rating to a “hold” rating and lowered their price target for the stock from $77.00 to $40.00 in a report on Wednesday, October 4th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $67.00 price target on shares of Mallinckrodt in a report on Thursday, October 5th.

Mallinckrodt (NYSE:MNK) opened at $21.30 on Friday. The stock has a market cap of $2,020.00, a price-to-earnings ratio of -1,065.00, a PEG ratio of 0.42 and a beta of 1.30. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. Mallinckrodt has a 1-year low of $19.00 and a 1-year high of $55.32.

Mallinckrodt (NYSE:MNK) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.17. The company had revenue of $793.90 million during the quarter, compared to the consensus estimate of $808.93 million. Mallinckrodt had a net margin of 11.43% and a return on equity of 14.79%. The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.04 earnings per share. research analysts predict that Mallinckrodt will post 7.2 EPS for the current fiscal year.

In other news, Director David R. Carlucci purchased 10,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were acquired at an average price of $21.83 per share, with a total value of $218,300.00. Following the completion of the transaction, the director now owns 26,020 shares of the company’s stock, valued at approximately $568,016.60. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Steven J. Romano purchased 2,000 shares of the business’s stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $21.96 per share, for a total transaction of $43,920.00. The disclosure for this purchase can be found here. Insiders purchased 30,460 shares of company stock valued at $659,486 over the last 90 days. 0.77% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. State of Alaska Department of Revenue bought a new stake in Mallinckrodt during the fourth quarter valued at $129,000. Sterling Capital Management LLC bought a new stake in Mallinckrodt during the second quarter valued at $204,000. Shelton Capital Management bought a new stake in Mallinckrodt during the third quarter valued at $205,000. Cubist Systematic Strategies LLC boosted its position in Mallinckrodt by 748.1% during the third quarter. Cubist Systematic Strategies LLC now owns 7,989 shares of the company’s stock valued at $299,000 after acquiring an additional 7,047 shares during the last quarter. Finally, Pinnacle Associates Ltd. boosted its position in Mallinckrodt by 69.8% during the third quarter. Pinnacle Associates Ltd. now owns 8,025 shares of the company’s stock valued at $300,000 after acquiring an additional 3,300 shares during the last quarter.

WARNING: “Mallinckrodt PLC (MNK) Given Consensus Rating of “Hold” by Analysts” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2018/01/20/mallinckrodt-plc-mnk-given-consensus-rating-of-hold-by-analysts.html.

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.